Endotec Calls FDA’s AIP Decision “Extreme,” Probes Appeal Mechanisms

Endotec is asking CDRH Ombudsman Les Weinstein to assist in obtaining a formal review of the FDA's Feb. 14 decision to invoke an application integrity policy (AIP) for the firm's submissions